skip to primary navigationskip to content
 

Life sciences equity crowdfunding platform, Capital Cell shortlisted for international award

last modified Jun 23, 2017 03:38 PM
Shortlisted for the Best International Growth Business award at the UK Business Angels Association Investment Awards 2017

Today, ideaSpace West members, Capital Cell, Europe’s first equity crowdfunding platform specialised in life science, has been shortlisted for the prestigious Best International Growth Business award at the UK Business Angels Association Investment Awards 2017.

Capital Cell has been trading in Spain for just over 2 years, and has successfully closed 14 life science crowdfunding campaigns, including the country’s largest life science crowdfunding campaign of over 1.2M, for a potential therapeutic cure for MS.

Scaling-up from this Spanish platform, Capital Cell UK has just launched at www.capitalcell.co.uk, with a range of companies solving unmet needs from malaria control to female fertility enhancement and autoimmune disease.

In recognition of their contribution to the European life science ecosystem, the company has now been shortlisted for the Best International Growth Business award at the UK Business Angels Association Investment Awards 2017.

‘We are absolutely thrilled that Capital Cell has been recognised so early on in it’s expansion into the UK,’ says Laura Ferguson, UK Director. ‘The reception to our arrival has been overwhelmingly positive from players throughout the life science ecosystem, including specialised investors such as Angels in MedCity, with whom we are collaborating closely, as well as the NHS innovation, science parks and startup incubators. It’s wonderful to have that traction formally recognised’.

The UKBAA black-tie awards dinner will take place on July the 6th, at the Dorchester Hotel, London, with 300 leading innovators and investors assembled to celebrate the best of UK business.page1image17296page1image17456page1image17616

Capital Cell has already proven itself as a platform for early stage investment in a very challenging environment’, Chairman Ian Tomlinson adds, ‘so we are extremely excited about scaling up in the UK, which is a global leader not only in life science innovation but also in equity crowdfunding. As an investment area, life science has the potential for both huge social impact and significant financial returns and the companies listed on Capital Cell are all trying to solve a major unmet medical need. By opening up these investment opportunities to more people we hope to be able to help the UK remain at the cutting edge of life science commercialisation.'

About Capital Cell: 

Capital Cell was founded by Daniel Oliver, CEO, and has been trading in Spain for just over 2 years from their main operational office in Barcelona. Following investment into Capital Cell of more than 500k, including UK and Spanish business angels as well as “crowd” investment from their own 300kcrowdfunding campaign closed in March 2017, the company has now launched in the UK. Daniel Oliver remains in majority control of the company, with the UK launch being led alongside Laura Ferguson, UK Director.

Ian Tomlinson, UK Chairman (www.stevenagecatalyst.com/about/board_directors/ian_tomlinson/) was the co-founder of Domantis Ltd which was acquired by GSK for $454 million in 2006, and is also current Chairman of Stevenage BioScience Catalyst.

For more information, please contact:

Katie Anderton

Head of Marketing and Capital Cell

katie@capitalcell.net 

RSS Feed Latest news

The writing's on the wall: Blackboard win WOW Award

Sep 18, 2017

Ally recognised for impact on student success

Your liver on a microchip - a revolution in drug development

Aug 17, 2017

Funding for a cutting edge alternative to animal testing

An interview with Steve Marsh from GeoSpock

Aug 17, 2017

Steve talks extreme data and building the tech of the future

Shining a light on Polysolar

Aug 14, 2017

Generating power through sustainable energy sourcing

Sparrho spreads its wings

Jul 17, 2017

Sparrho raises $3 million to democratize access to science research

View all news